Genotype-phenotype correlations in hepatocellular adenoma: An update of MRI findings

Diagnostic and Interventional Radiology

Volumn 20, Issue 3, 2014, Pages 193-199

  Thomeer, Maarten G ^a   Bröker, Mirelle E E ^a   de Lussanet, Quido ^b   Biermann, Katharina ^a   Dwarkasing, Roy S ^a   de Man, Rob ^a   IJzermans, Jan N ^a   de Vries, Marianne ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Medical Center Zuiderzee   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BILIRUBIN; C REACTIVE PROTEIN; FATTY ACID BINDING PROTEIN; GADOBENATE DIMEGLUMINE; GADOXETIC ACID; GLUTAMATE AMMONIA LIGASE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; ORGANIC ANION TRANSPORTER; SERUM AMYLOID A; CONTRAST MEDIUM; GADOLINIUM; GADOLINIUM PENTETATE;

BILIARY EXCRETION; COMPUTER ASSISTED TOMOGRAPHY; DOWN REGULATION; ECHOGRAPHY; FATTY LIVER; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; GLYCOGEN STORAGE DISEASE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPID STORAGE; LIVER ADENOMA; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CIRRHOSIS; LIVER FOCAL NODULAR HYPERPLASIA; LIVER HEMORRHAGE; LIVER RUPTURE; MALIGNANT TRANSFORMATION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; ADENOMA, LIVER CELL; COMPLICATION; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; FEMALE; FOCAL NODULAR HYPERPLASIA; GENETICS; GENOTYPE; IMAGE ENHANCEMENT; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PATHOLOGY; PHENOTYPE; YOUNG ADULT;

ADENOMA, LIVER CELL; BETA CATENIN; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOCAL NODULAR HYPERPLASIA; GADOLINIUM; GADOLINIUM DTPA; GENOTYPE; HUMANS; IMAGE ENHANCEMENT; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PHENOTYPE; YOUNG ADULT;

EID: 84899729067     PISSN: 13053825     EISSN: 13053612     Source Type: Journal    
DOI: 10.5152/dir.2013.13315     Document Type: Review

References (39)

1. Hussain SM, van den Bos IC, Dwarkasing RS, Kuiper JW, den Hollander J. Hepatocellular adenoma: findings at stateof-the-art magnetic resonance imaging, ultrasound, computed tomography and pathologic analysis. Eur Radiol 2006; 16:1873-1886. [CrossRef]
2. Hussain SM, Terkivatan T, Zondervan PE, et al. Focal nodular hyperplasia: findings at state-of-the-art MR imaging, US, CT, and pathologic analysis. Radiographics 2004; 24:3-19. [CrossRef]
3. van Aalten SM, de Man RA, IJzermans, Terkivatan T. Systematic review of haemorrhage and rupture of hepatocellular adenomas. Br J Surg 2012; 99:911-916. [CrossRef]
4. Buhler H, Pirovino M, Akobiantz A, et al. Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use. Gastroenterology 1982; 82:775-782.
5. Reddy KR, Schiff ER. Approach to a liver mass. Semin Liver Dis 1993; 13:423-435. [CrossRef]
6. Rooks JB, Ory HW, Ishak KG, et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979; 242:644-648. [CrossRef]
7. Steinbrecher UP, Lisbona R, Huang SN, Mishkin S. Complete regression of hepatocellular adenoma after withdrawal of oral contraceptives. Dig Dis Sci 1981; 26:1045-1050. [CrossRef]
8. Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007; 46:740-748. [CrossRef]
9. Bioulac-Sage P, Balabaud C, Bedossa P, et al. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol 2007; 46:521-527. [CrossRef]
10. Bluteau O, Jeannot E, Bioulac-Sage P, et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 2002; 32:312-315. [CrossRef]
11. Akiyama TE, Ward JM, Gonzalez FJ. Regulation of the liver fatty acid-binding protein gene by hepatocyte nuclear factor 1alpha (HNF1alpha). Alterations in fatty acid homeostasis in HNF1alpha-deficient mice. J Biol Chem 2000; 275:27117-27122.
12. van Aalten SM, Verheij J, Terkivatan T, Dwarkasing RS, de Man RA, IJzermans JN. Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. J Hepatol 2011; 55:120-125. [CrossRef]
13. Ronot M, Bahrami S, Calderaro J, et al. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology 2011; 53:1182-1191. [CrossRef]
14. Jeannot E, Mellottee L, Bioulac-Sage P, et al. Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage. Diabetes 2010; 59:1836-1844. [CrossRef]
15. Bioulac-Sage P, Laumonier H, Couchy G, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 2009; 50:481-489. [CrossRef]
16. Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 2013; 144:888-902. [CrossRef]
17. Cadoret A, Ovejero C, Saadi-Kheddouci S, et al. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res 2001; 61:3245-3249.
18. Bioulac-Sage P, Blanc JF, Rebouissou S, Balabaud C, Zucman-Rossi J. Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol 2007; 13:2649-2654.
19. Bioulac-Sage P, Rebouissou S, Sa Cunha A, et al. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology 2005; 128:1211-1218. [CrossRef]
20. Bioulac-Sage P, Cubel G, Taouji S, et al. Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes. Am J Surg Pathol 2012; 36:1691-1699. [CrossRef]
21. van Aalten SM, Thomeer MG, Terkivatan T, et al. Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classification. Radiology 2011; 261:172-181. [CrossRef]
22. Bieze M, van den Esschert JW, Nio CY, et al. Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium. AJR Am J Roentgenol 2012; 199:26-34. [CrossRef]
23. Laumonier H, Bioulac-Sage P, Laurent C, Zucman-Rossi J, Balabaud C, Trillaud H. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology 2008; 48:808-818. [CrossRef]
24. Grazioli L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005; 236:166-177. [CrossRef]
25. Yoneda N, Matsui O, Kitao A, et al. Beta-catenin-activated hepatocellular adenoma showing hyperintensity on hepatobiliary-phase gadoxetic-enhanced magnetic resonance imaging and overexpression of OATP8. Jpn J Radiol 2012; 30:777-782. [CrossRef]
26. Fidler J, Hough D. Hepatocyte-specific magnetic resonance imaging contrast agents. Hepatology 2011; 53:678-682. [CrossRef]
27. Yoneda N, Matsui O, Kitao A, et al. Hepatocyte transporter expression in FNH and FNH-like nodule: correlation with signal intensity on gadoxetic acid enhanced magnetic resonance images. Jpn J Radiol 2012; 30:499-508. [CrossRef]
28. Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009; 44:793-798. [CrossRef]
29. Pascolo L, Cupelli F, Anelli PL, et al. Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents. Biochem Biophys Res Commun 1999; 257:746-752. [CrossRef]
30. Thomeer MG, Willemssen FE, Biermann KK, et al. MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents. J Magn Reson Imaging 2013 doi: 10.1002/jmri.24281. [CrossRef]
31. Laumonier H, Cailliez H, Balabaud C, et al. Role of contrast-enhanced sonography in differentiation of subtypes of hepatocellular adenoma: correlation with MRI findings. AJR Am J Roentgenol 2012; 199:341-348. [CrossRef]
32. Wang HL, Anatelli F, Zhai QJ, Adley B, Chuang ST, Yang XJ. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med 2008; 132:1723-1728.
33. Palmer PE, Christopherson WM, Wolfe HJ. Alpha1-antitrypsin, protein marker in oral contraceptive-associated hepatic tumors. Am J Clin Pathol 1977; 68:736-739.
34. van der Windt DJ, Kok NF, Hussain SM, et al. Case-orientated approach to the management of hepatocellular adenoma. Br J Surg 2006; 93:1495-1502. [CrossRef]
35. Noels JE, van Aalten SM, van der Windt DJ, et al. Management of hepatocellular adenoma during pregnancy. J Hepatol 2011; 54:553-558. [CrossRef]
36. van Aalten SM, Broker ME, Busschbach JJ, et al. Pregnancy and liver adenoma management: PALM-study. BMC Gastroenterol 2012; 12:82. [CrossRef]
37. Broker ME, IJzermans JN, van Aalten SM, de Man RA, Terkivatan T. The management of pregnancy in women with hepatocellular adenoma: a plea for an individualized approach. Int J Hepatol 2012; 2012:725-735. [CrossRef]
38. Psatha EA, Semelka RC, Armao D, Woosley JT, Firat Z, Schneider G. Hepatocellular adenomas in men: MRI findings in four patients. J Magn Reson Imaging 2005; 22:258-264. [CrossRef]
39. Howell RR, Stevenson RE, Ben-Menachem Y, Phyliky RL, Berry DH. Hepatic adenomata with type 1 glycogen storage disease. JAMA 1976; 236:1481-1484. [CrossRef]